2,5-Dimethoxy-4-(2-fluoroethyl)amphetamine
| Clinical data | |
|---|---|
| Other names | DOEF; 2,5-Dimethoxy-4-(2-fluoroethyl)amphetamine; 4-(2-Fluoroethyl)-2,5-dimethoxyamphetamine |
| Routes of administration | Oral[1] |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Onset of action | 1–2 hours[1] Peak: 3 hours[1] |
| Duration of action | 12–16 hours[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C13H20FNO2 |
| Molar mass | 241.306 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (what is this?) (verify) | |
2,5-Dimethoxy-4-(2-fluoroethyl)amphetamine (DOEF) is a psychedelic drug of the phenethylamine, amphetamine, and DOx families.[1][2][3]
Use and effects
In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists DOEF's dose as 2 to 3.5 mg orally and its duration as 12 to 16 hours.[1] The drug's onset was 1 to 2 hours and peak effects occurred after 3 hours.[1] The effects of DOEF were reported to include unworldliness, closed-eye imagery no appreciable open-eye visuals or not highly visual, time dilation, music and erotic enhancement, no body discomfort, insomnia, and sleep disruption, among others.[1]
Interactions
Chemistry
Synthesis
The chemical synthesis of DOEF has been described.[1]
Analogues
Analogues of DOEF include 2C-EF, DOET, DOTFE, DOPF, and DOTFM, among others.[1][4][5]
History
DOEF was first described in the scientific literature by Alexander Shulgin and colleagues in 1988.[6] Subsequently, it was described in greater detail by Shulgin in PiHKAL in 1991.[1]
Society and culture
Legal status
DOEF is a controlled substance in Canada under phenethylamine blanket-ban language.[7]
See also
References
- ^ a b c d e f g h i j k "DOEF Entry". PiHKAL.
- ^ Gerdes JM, Mathis CA, Shulgin AT (1988). "Synthesis of 1-[2′,5′-dimethoxy-4′-(β-fluoroethyl) phenyl]-2-aminopropane: studies related to 18F-labeled serotonin receptor ligands". Tetrahedron Letters. 29 (50): 6537–6539. doi:10.1016/S0040-4039(00)82391-6.
- ^ Trachsel D (2012). "Fluorine in psychedelic phenethylamines". Drug Testing and Analysis. 4 (7–8): 577–590. doi:10.1002/dta.413. PMID 22374819.
- ^ Trachsel D (2012). "Fluorine in psychedelic phenethylamines". Drug Test Anal. 4 (7–8): 577–590. doi:10.1002/dta.413. PMID 22374819.
- ^ Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. ISBN 978-3-03788-700-4. OCLC 858805226.
- ^ Gerdes JM, Mathis CA, Shulgin AT (1988). "Synthesis of 1-[2′,5′-dimethoxy-4′-(β-fluoroethyl)phenyl]-2-aminopropane:studies related to 18F-labeled serotonin receptor ligands". Tetrahedron Letters. 29 (50): 6537–6539. doi:10.1016/S0040-4039(00)82391-6. Retrieved 27 November 2025.
- ^ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.